INVESTORS

Investor Relations

Recent News
Apr 17, 2018
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting

- Two posters reporting activity for SRA737 with PARPi (in CCNE1-driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this...

Mar 19, 2018
Sierra Oncology to Present at the Future Leaders in the Biotech Industry Conference in New York

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Mar 14, 2018
Late-Breaking Abstract Reporting SRA737 Preclinical Activity in CCNE1-Driven and PARPi-Resistant Cancers Accepted for AACR 2018 Annual Meeting

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

View all news releases

Annual Meeting of Stockholders

Date: June 12, 2018
Time: 10:00 am PT
Location: Four Seasons Hotel, 791 West Georgia Street, Vancouver, British Columbia

Proxy Documents:

Investor Enquiries

James Smith, Vice President Corporate Affairs
[email protected]

Sign up for investor alerts


NASDAQ: SRRANASDAQ: DNAI